Sinacilin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sinacilin

Property Description
Active ingredient Amoxicillin (Amoxicillin trihydrate)
Form Capsule, tablet, powder for oral suspension
Pharmacological class Antibiotic (beta-lactam, aminopenicillin subgroup)
Common use Systemic treatment of bacterial infections
Origin Semisynthetic penicillin

Sinacilin is a prescription-only medicinal preparation whose sole active substance is Amoxicillin (Amoxicillin trihydrate). The drug is fundamentally classified as an antibiotic belonging to the beta-lactam class, specifically the aminopenicillin subgroup. This class is clinically recognized for providing broad-spectrum activity against a wider range of susceptible microorganisms compared to narrow-spectrum penicillins. Amoxicillin is a semisynthetic penicillin designed for enhanced oral absorption, a key feature differentiating it from its structural analogue, Ampicillin.

Composition and Available Drug Forms

As a single-ingredient product, Sinacilin contains the Amoxicillin active substance along with pharmaceutical excipients appropriate for its presentation. The medicine is primarily intended for oral administration and is supplied in several dosage form(s) to suit different patient groups. These commonly include the solid forms, such as the capsule and tablet, and the liquid form, supplied as a powder for oral suspension that must be reconstituted with water before use. This availability of a powder for suspension is crucial for pediatric patients.

How Does Amoxicillin Work at a High Level?

Amoxicillin is recognized for its critical role in managing bacterial infections globally. The fundamental physiological action relies on the inhibition of bacterial cell wall synthesis, a process that is lethal to the bacteria. This mechanism causes the susceptible microorganisms to lose structural integrity and rupture (bacteriolysis), providing an essential and direct intervention against systemic bacterial infections.

Regulatory References

  1. Amoxicillin on WHO Essential Medicines List

What side effects are possible with Sinacilin?

Possible Side Effects and Safety Information

The official safety profile of Sinacilin (Amoxicillin) is structured by governmental regulatory bodies based on the frequency and system-organ class affected. Adverse reactions are classified according to clinical data.

Frequency-Classified Adverse Reactions

Classification Identified Adverse Reactions (Examples)
Common (>1 in 100 people) Nausea, Diarrhea, Rash, Vomiting.
Uncommon (1 in 100 to 1 in 1,000) Urticaria (hives), Pruritus (itching).
Rare/Very Rare (<1 in 1,000) Severe hypersensitivity (anaphylaxis), Severe skin conditions (SJS/TEN), Hepatitis, Hematological effects (e.g., Anemia, Leukopenia), Pseudomembranous colitis.

System-Organ-Class Safety Notes

The adverse reactions are officially documented across several physiological systems. Most commonly reported are Gastrointestinal Disorders and Skin and Subcutaneous Tissue Disorders. Other systems include Immune System Disorders, Nervous System Disorders (e.g., convulsions, often associated with high doses or impaired renal function), Hepatobiliary Disorders (liver issues), and Renal and Urinary Disorders (e.g., crystalluria).

Serious Reactions and Safety Considerations

The regulatory profile highlights the potential for serious adverse reactions, including fatal anaphylactic reactions and severe cutaneous adverse reactions like Stevens-Johnson syndrome (SJS). Safety notes exist for specific populations. For instance, the elimination of Amoxicillin is reduced in patients with impaired renal function, which necessitates specialized monitoring. Additionally, a non-allergic maculopapular rash is associated with use in patients diagnosed with infectious mononucleosis.

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose profile for this type of penicillin-class antibiotic is defined by a set of expected clinical manifestations and severe potential outcomes, primarily affecting the gastrointestinal and renal systems.

Overdose may lead to common gastrointestinal symptoms, including nausea, vomiting, and diarrhea. These effects can, in turn, result in fluid and electrolyte imbalances that require supportive care.

Serious Outcomes and Emergency Action

Severe outcomes documented in official regulatory sources include crystalluria (the formation of drug crystals in the urine), which can progress to renal impairment or kidney failure. Additionally, convulsions (seizures) have been reported, particularly in individuals with existing impaired kidney function or those receiving very high doses.

Urgent medical attention is required immediately if convulsions occur, or if signs of significantly decreased urination or other symptoms of renal impairment are observed. Treatment involves discontinuing the product and initiating general symptomatic and supportive measures. Maintaining adequate fluid intake is a stated necessity to help reduce the risk of crystalluria. Hemodialysis may be used to remove the drug from the body in severe cases of overexposure.

Therapeutic Uses of Sinacilin

What Sinacilin Treats: Main Uses and Benefits

Sinacilin, which contains Amoxicillin, is an antibiotic generally used to address symptoms related to acute bacterial infection across multiple body systems. The medication is applied in clinical settings relevant for easing distress associated with these acute episodes.

Amoxicillin is commonly used in therapeutic domains involving certain distressing symptoms in the ears (otitis media), nose, throat (pharyngitis), urinary tract, and skin. It is also a key component in multi-drug regimens used to address H. pylori bacteria that may cause chronic peptic ulcers.

The drug is relevant in contexts marked by increased discomfort or tension, and may assist with managing symptoms such as fever, sore throat, ear pain, and malaise that accompany systemic imbalance. It supports general well-being during symptomatic phases, particularly when these symptoms interfere with routine activities.

Quick Fact: Relief for Acute Discomfort
Sinacilin supports the patient during difficult episodes by easing distress when symptoms create noticeable physiological strain in the ears, throat, and lungs.

Regulatory References

  1. MedlinePlus Drug Information on Amoxicillin

Eligibility and Restrictions for Use

Who Can and Cannot Use Sinacilin?

Eligibility for using Sinacilin, which contains Amoxicillin, is strictly defined by government regulatory documents based on contraindications and specific population restrictions.

Sinacilin is contraindicated and must not be used by patients with a known history of severe immediate hypersensitivity reaction (e.g., anaphylaxis) to any penicillin or other beta-lactam antibacterial drug (e.g., cephalosporins). Use is also not recommended for patients with or suspected of having Infectious Mononucleosis or Lymphatic Leukemia due to an officially documented high risk of developing a specific skin rash.

Conditional Eligibility

Population Group Regulatory Status and Condition
Renal Impairment Conditional; required use modification for severe renal impairment (GFR < 30 mL/min).
Hepatic Impairment Conditional; caution is advised, and liver function monitoring is recommended during prolonged use.
Pediatric Use Established for children ge 3 months. Conditional use for neonates (le 3 months) due to delayed elimination.
Pregnancy/Lactation Conditional; use only if clearly needed, as drug is excreted in human milk, requiring caution against infant sensitization.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define specific interactions for Sinacilin (Amoxicillin) that affect drug exposure and co-administration requirements. The interaction profile is structured around effects on renal clearance, pharmacodynamic risks, and co-administration risks.


Documented Exposure and Coagulation Risk

  • Co-administration with Probenecid officially results in increased and prolonged blood levels of Sinacilin by decreasing its renal tubular secretion.
  • Oral Anticoagulants (such as warfarin) may officially cause an increase in prothrombin time (INR), which necessitates the monitoring of coagulation parameters during concurrent use due to an elevated risk of bleeding.
  • Methotrexate clearance may be delayed, and its serum levels prolonged, due to Sinacilin's potential to interfere with its renal tubular secretion.

Pharmacological and Other Interferences

  • The efficacy of Combined Oral Contraceptives may be officially reduced by Sinacilin, a risk linked to altering gut flora.
  • Allopurinol co-administration is officially associated with an increased incidence of developing a skin rash.
  • Other antibacterials classified as bacteriostatic agents (e.g., macrolides, tetracyclines) may officially interfere with the bactericidal effect of Sinacilin.

Procedural Constraint: Sinacilin can cause false-positive reactions in certain non-enzymatic urine glucose tests (e.g., Clinitest), leading to the official recommendation of enzymatic glucose oxidase methods for glucose testing.

Mechanism of Action

Sinacilin is an aminopenicillin that selectively targets bacterial organisms. The drug is an irreversible inhibitor of the transpeptidation stage in bacterial cell wall biosynthesis. Its molecular target is a class of bacterial enzymes known as penicillin-binding proteins (PBPs), which are located on the inner surface of the bacterial cell membrane.

The beta-lactam moiety of Sinacilin forms a stable, covalent intermediate with the active site of the PBP, specifically the transpeptidase domain. This acyl enzyme intermediate prevents the PBP from catalyzing the cross-linking of linear peptidoglycan strands, a critical process for maintaining cell wall rigidity and integrity. This inhibition disrupts the assembly of a structurally sound cell wall, particularly in actively dividing cells. The resulting intracellular cascade involves the activation of bacterial autolytic enzymes (autolysins). The weakened cell wall structure, coupled with continuous internal osmotic pressure, leads to localized structural defects, membrane protrusion, and ultimately, cell wall lysis, a systemic physiological consequence resulting in bacterial cell destruction.

Dosage and Administration Information

The instructions for using Sinacilin (amoxicillin) describe the steps for administration, dosage, and scheduling to ensure proper use.

Administration and Dosing Schedule

Sinacilin is for oral use and can be taken with or without food, although certain formulations may be administered at the start of a light meal. The medication is typically taken on a fixed schedule, such as every 8 hours (three times a day) or every 12 hours (twice a day). The dose is determined by the severity of the condition and the patient's weight, particularly for pediatric users. Standard adult dosages range from 250 mg to 875 mg per dose, depending on the regimen and severity.

Preparation and Procedural Steps

Dosage Form Preparation Requirement Dosing Instruction
Capsules/Tablets Swallow whole with water; do not crush or chew (unless dispersible or chewable form). Take at the exact prescribed time intervals.
Oral Suspension Shake the bottle well before each use to ensure the medication is evenly mixed. Must be properly reconstituted with a specified amount of water by a pharmacist or by following the specific preparation steps. Measure the dose only with a dedicated measuring device (e.g., oral syringe or spoon), not a household spoon.
Completion of Course The full prescribed course must be completed, even if the user feels better, to achieve the intended effect.

Missed Dose Rule

If a dose is forgotten, the instruction is to take it as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped, and the user should resume the regular schedule. A double dose must not be taken to compensate for the missed one.

Recent Clinical Evidence

Sinacilin: Recent Clinical Evidence

The clinical evaluation of Sinacilin (Amoxicillin) is based on numerous official clinical research studies, primarily Randomized Controlled Trials (RCTs) and large Systematic Reviews that combine the findings from multiple trials. The evidence base is structured to address specific regulatory indications.


Evidence for Use in Acute Ear, Nose, and Throat Infections

Research for conditions like acute otitis media and pharyngitis primarily used short-term RCTs to explore outcomes related to physical discomfort and symptom change over the observed interval. The research consists of a high volume of consistent findings. However, long-term outcomes are not fully established following multiple treatments, and data on the long-term impact on inner ear status remain limited.

Evidence for Use in Lower Respiratory Tract Infections

Research includes Non-inferiority Trials for Community-Acquired Pneumonia (CAP), focusing on non-severe cases in children and adults. Studies monitored treatment failure endpoints (rate of needed re-treatment) and the recorded time-to-symptom improvement. Data for certain groups remain insufficient for individuals presenting with more severe or complicated lower respiratory tract issues.

Evidence for Use in H. Pylori Eradication Regimens

Sinacilin was studied for its use as a core component in multi-drug regimens research examined for H. pylori infection. Research examined the eradication rate and measures of ulcer recurrence. The measured eradication rates was associated with the resistance patterns of companion medicines, and comparative evidence for using the drug after initial treatment failure remains insufficient.

Studies in Distinct Patient Populations and Research Gaps

Clinical trials have included studies focusing on pediatric patients and their outcomes. Conversely, data for older adults are often based on modest sample sizes, and follow-up durations were limited. Scientific sources note areas of uncertainty, including inconclusive comparative evidence regarding the optimal duration of therapy (e.g., 5-day versus 7-day regimens), and a general lack of information concerning outcomes for patients with certain comorbidities.

Frequently Asked Questions (FAQ)

Common questions about Sinacilin (FAQ)

Q: Is it true that Sinacilin can affect birth control pills?

A: Official drug documents state that Sinacilin may reduce the effectiveness of combined oral contraceptives. This potential interaction is linked to the medicine possibly altering gut flora, which can lead to lower estrogen reabsorption in the body. Regulatory sources contain details regarding this potential interaction.

Q: Can Sinacilin be taken by older adults or seniors?

A: Regulatory sources advise that for older adults, particularly those with reduced kidney function, the body may clear Sinacilin more slowly. Dosing consideration may be necessary in cases of severe renal (kidney) impairment. Clinical data for this population group is noted to be based on more modest sample sizes.

Q: What is the difference between Sinacilin and other similar sounding medicines?

A: Sinacilin is the brand name for Amoxicillin, which is classified as a semi-synthetic aminopenicillin. Official documentation describes it as being specifically designed for enhanced absorption when taken orally, which is a key difference from its close chemical relative, Ampicillin.

Q: Can lifestyle factors like smoking or alcohol consumption affect how Sinacilin works?

A: Official drug documents for Sinacilin do not typically list a specific prohibition against alcohol consumption during treatment. The interaction profile focuses primarily on drug-drug interactions and specific procedural constraints.

Q: Is there a maximum amount of time someone is described to take Sinacilin?

A: The required duration of treatment is determined by the specific type and severity of the infection, and this is detailed in the prescribing information. Official regimens are typically found to range from 7 to 14 days, though the optimal duration of therapy is an area of ongoing research and can vary based on the specific condition.

Q: Does Sinacilin lose its effectiveness over time?

A: Official warnings emphasize the public health concern regarding the development of drug-resistant bacteria when antibiotics are used inappropriately. Completing the full prescribed course and confirming the infection is bacterial are factors considered important for minimizing the risk of resistance development.

Q: What is the general safety profile of Sinacilin according to regulatory bodies?

A: The general safety profile is consistent with other penicillins. Most commonly reported issues relate to gastrointestinal problems, such as nausea and diarrhea, and certain types of rashes. Regulatory documents classify the risk of severe hypersensitivity reactions (anaphylaxis) as rare but serious.

Q: How long does Sinacilin stay in your system after the last dose?

A: In healthy adults, Sinacilin is rapidly eliminated by the body. The drug has an elimination half-life of approximately one hour. The majority of the drug (60% to 70%) is described as being excreted unchanged in the urine within the first six hours of administration.

Q: What happens if someone accidentally takes more Sinacilin than recommended?

A: Official patient information notes that taking an accidental extra dose is often described as unlikely to result in serious consequences. However, very high doses may lead to severe gastrointestinal effects like nausea, vomiting, or diarrhea. In individuals with impaired kidney function, high doses have been rarely associated with effects on the nervous system, such as convulsions.

Q: What does the research say about Sinacilin's use in different populations?

A: Research supports its use in pediatric patients starting at three months of age. Data is also available for those with reduced liver or kidney function, though dosing consideration may be required, and caution is advised in these cases. Research notes limitations in the data for older adults and those with certain underlying health conditions.

Q: Are there any dietary restrictions mentioned in the official guidance for Sinacilin?

A: No mandatory dietary restrictions are listed in the official guidance. Sinacilin may be taken with or without food, as official guidance indicates it can be taken regardless of food intake.

Q: Does Sinacilin affect the ability to drive or operate machinery?

A: Some rare adverse effects, such as dizziness or nervous system issues like convulsions, are noted in official documents. Regulatory information notes these potential effects and patients may be cautioned about performing focused tasks until they know how the medicine affects them.

Q: Is the medication Sinacilin ever used in combination with other drugs?

A: Yes, Sinacilin is officially indicated for use as a core component in multi-drug regimens for specific conditions. A well-known example is its use alongside other antimicrobials and acid-reducing agents for the eradication of H. pylori infection.

Q: Why does Sinacilin sometimes cause a rash?

A: Rashes can be a sign of a common, non-serious side effect or, in rare cases, a serious allergic reaction. Official documents specifically warn that individuals with infectious mononucleosis have an elevated risk of developing a non-allergic maculopapular rash when using the drug.

Q: Are there any known issues with Sinacilin for people with diabetes?

A: Official guidance warns that Sinacilin can interfere with certain non-enzymatic methods used to test urine glucose, potentially causing false-positive results. It is officially recommended that people with diabetes use enzymatic glucose oxidase methods for monitoring blood sugar while taking this medicine.

Q: What is the evidence theme regarding resistance development with Sinacilin?

A: Official documentation strongly emphasizes that prescribing Sinacilin for a bacterial infection should be based on clinical evidence or confirmed susceptibility. The unnecessary use of the medicine is associated with the increased risk of bacteria developing resistance.

Q: Is Sinacilin a chemically synthesized drug or derived from a natural source?

A: Sinacilin (Amoxicillin) is officially classified as a semisynthetic penicillin. This means it is chemically manufactured using a base component, the penicillin nucleus, which is naturally derived from certain types of mold.

Q: Is it possible to have an allergic reaction to the inactive ingredients in Sinacilin?

A: While the primary contraindication is for allergy to penicillin or related beta-lactam drugs, official warnings advise that patients with known sensitivities to multiple allergens may be at higher risk. The full list of inactive ingredients is provided in the official product information.

Q: Are there any specific official warnings for people with a history of seizures using Sinacilin?

A: Official documents list convulsions (seizures) as a rare adverse effect, often associated with very high doses or poor renal (kidney) function. While this reaction is noted, the drug label does not typically provide a specific contraindication for a general history of seizures.

Q: What is the main reason Sinacilin might fail to treat a condition?

A: One key reason noted in official warnings is that the infection may be caused by organisms that are not susceptible to Sinacilin, such as viruses or bacteria that have developed resistance. The overgrowth of non-susceptible organisms during prolonged use is also mentioned as a potential issue.

How should Sinacilin be stored and disposed of?

How to Store and Dispose of Sinacilin

Storage conditions for Sinacilin (Amoxicillin) depend on the formulation.


Storage Requirements

  • Solid Forms (Capsules/Tablets): Store at controlled room temperature (20 C to 25 C) and protect from moisture and excessive heat.
  • Liquid Suspension (Reconstituted): Must be stored in a refrigerator (2 C to 8 C) and must not be frozen.
  • Stability: The reconstituted suspension must be discarded after 14 days.

Safety and Disposal

Keep all forms of the medicine in a tightly closed container and out of the sight and reach of children.

Do not dispose of unused or expired Sinacilin via wastewater or household trash. Dispose of the medication according to local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sinacilin found in:

A-Z Index: